Menopause Ultra
Natural health product licensed in Canada
- Other names
- Menopause relief
- Licence holder
- Advanced Orthomolecular Research Inc.
- NPN or DIN-HM
- 80119717
- Status
- Active licence
- Licence date
- 4 July 2022
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Conditions légales
Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Crocus sativus Source : Stigmates Potency : 3.48 % Crocin | Not specified | Not calculated |
| Trigonella foenum-graecum Source : Graine Potency : 30 % Saponins | Not specified | Not calculated |
| Trigonella foenum-graecum Source : Graine Potency : 3 % Trigonelline | Not specified | Not calculated |
| Trigonella foenum-graecum Source : Graine Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 5 g Potency : 10 % Protodioscin | 250 mg | Not calculated |
| Crocus sativus Source : Stigmates Extract : Matériel brut sec Extraction ratio : 3:1 Dry plant equivalent : 42 mg Potency : 0.03 % 2,6,6-Trimethylcyclohexa-1,3-diene-1-carbaldehyde | 14 mg | Not calculated |
Non-medicinal ingredients
Dextrine, Stéaryl fumarate de sodium, Maltodextrine, Hypromellose, Cellulose microcristalline, Poudre de racine de carotte, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Menopause ultra contains fenugreek husk seed extract, which studies show: : help support post and peri-menopausal discomforts, helps to support healthy estrogen balance. Helps relives symptoms associated with menopause such as hot flashes, night sweats, interrupted sleep pattern/insomnia, irritability and joint and muscular discomfort thereby supporting quality of life. Menopause ultra also contains Affron® a registered brand of saffron that helps to support mood balance. Affron ® helps to relieve restlessness and/or nervousness (calmative), supports positive effects on symptoms of perceived stress such as, fatigue, weariness, and irritability, helps to reduce the symptoms of perceived stress, such as fatigue, weariness, and irritability.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80119717
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.